Abstract | OBJECTIVES: To provide evidence of the clinical efficacy of Xuebijing (XBJ) on blood coagulation in patients with sepsis. METHODS: We conducted this meta-analysis in The People's Hospital of Liaoning Province, Shenyang, China between December 2013 and May 2014. We searched a number of databases for relevant randomized controlled trials (RCTs) published before December 2013 using the keywords ' Xuebijing', 'coagulation' and ' sepsis'. Statistical analysis was performed with Review Manager 5.2 from the Cochrane Collaboration. RESULTS: Fourteen RCTs involving 867 patients were included. Compared with placebo, XBJ injection significantly improved platelets (mean differences [MD] = 42.14, 95% confidence interval [CI]: 22.42 - 61.86, p<0.00001), shortened the activated partial thromboplastin time (MD = -4.81, 95% CI: -7.86 - [-1.76], p=0.002), shortened the prothrombin time (MD = -2.33, 95% CI: -4.15 - [-0.51], p=0.01), and shortened the thrombin time (MD = -2.05, 95% CI: -3.52 - [-0.58], p=0.006). However, no significant difference was found between the XBJ injection and the placebo group for fibrinogen (MD = 0.21, 95% CI: -0.38 - 0.81, p=0.48). CONCLUSION:
Xuebijing injection may improve coagulopathy in patients with sepsis. High-quality and large sample clinical trials are needed for confirmation.
|
Authors | Si-Yuan Hou, Xing-Huo Feng, Chang-Liang Lin, Yong-Feng Tan |
Journal | Saudi medical journal
(Saudi Med J)
Vol. 36
Issue 2
Pg. 164-9
(Feb 2015)
ISSN: 0379-5284 [Print] Saudi Arabia |
PMID | 25719579
(Publication Type: Journal Article, Meta-Analysis)
|
Chemical References |
- Drugs, Chinese Herbal
- Xuebijing
|
Topics |
- Blood Coagulation Disorders
(drug therapy, etiology)
- Drugs, Chinese Herbal
(therapeutic use)
- Humans
- Sepsis
(complications)
|